Eupraxia's EREFS Data Shows Dose-Dependent EoE Improvements in Phase 1b/2a Trial
Event summary
- Eupraxia reported EREFS data from its Phase 1b/2a RESOLVE trial, showing dose-dependent improvements in EoE patients.
- 20 injections of EP-104GI resulted in a 65% mean reduction in EREFS scores at week 12.
- The Phase 2b portion of the RESOLVE trial is currently recruiting, with top-line data expected in Q4 2026.
- Eupraxia's Diffusphere™ technology aims to optimize local, controlled drug delivery for EoE.
The big picture
Eupraxia's positive EREFS data from the RESOLVE trial highlights the potential of its Diffusphere™ technology in optimizing local drug delivery for EoE. The dose-dependent improvements observed suggest a promising pathway for addressing the significant unmet medical need in this inflammatory-mediated disease. The upcoming Phase 2b trial results will be critical in determining the future of EP-104GI as a potential treatment option for EoE patients.
What we're watching
- Clinical Efficacy
- Whether the dose-dependent improvements in EREFS scores will translate into long-term clinical benefits for EoE patients.
- Regulatory Pathway
- The pace at which Eupraxia can advance EP-104GI through the Phase 2b trial and potentially secure regulatory approval.
- Market Potential
- How Eupraxia's Diffusphere™ technology could impact the treatment landscape for EoE and other inflammatory gastrointestinal diseases.
Related topics